JAZZ vs. PRGO, CORT, ITCI, CYTK, ELAN, BPMC, CERE, IONS, ASND, and LEGN
Should you be buying Jazz Pharmaceuticals stock or one of its competitors? The main competitors of Jazz Pharmaceuticals include Perrigo (PRGO), Corcept Therapeutics (CORT), Intra-Cellular Therapies (ITCI), Cytokinetics (CYTK), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), Cerevel Therapeutics (CERE), Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical preparations" industry.
Perrigo (NYSE:PRGO) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, community ranking, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.
95.9% of Perrigo shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 0.7% of Perrigo shares are owned by insiders. Comparatively, 4.4% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Jazz Pharmaceuticals received 334 more outperform votes than Perrigo when rated by MarketBeat users. Likewise, 80.54% of users gave Jazz Pharmaceuticals an outperform vote while only 66.75% of users gave Perrigo an outperform vote.
In the previous week, Perrigo had 3 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 9 mentions for Perrigo and 6 mentions for Jazz Pharmaceuticals. Perrigo's average media sentiment score of 0.77 beat Jazz Pharmaceuticals' score of 0.52 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.
Perrigo presently has a consensus price target of $40.67, suggesting a potential upside of 36.33%. Jazz Pharmaceuticals has a consensus price target of $192.75, suggesting a potential upside of 76.85%. Given Perrigo's higher possible upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Perrigo.
Jazz Pharmaceuticals has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Jazz Pharmaceuticals has a net margin of 8.61% compared to Jazz Pharmaceuticals' net margin of -0.17%. Perrigo's return on equity of 27.86% beat Jazz Pharmaceuticals' return on equity.
Perrigo has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.
Summary
Jazz Pharmaceuticals beats Perrigo on 13 of the 17 factors compared between the two stocks.
Get Jazz Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JAZZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Jazz Pharmaceuticals Competitors List
Related Companies and Tools
